Tarsus Pharmaceuticals

At Tarsus, we are looking for inspired individuals who are motivated to grow professionally, while building a best-in-class pharmaceutical company with a differentiated approach. Join us in advancing our mission to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients.

Who is Tarsus? We are a biopharmaceutical company focused on the development and commercialization of therapeutic candidates designed to address diseases with high unmet need across therapeutic categories, including eye care and infectious diseases.

We are advancing our pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA-approved in the United States for the treatment of Demodex blepharitis. In addition, we are developing TP-04 for the potential treatment of ocular rosacea and TP-05, an oral tablet for the prevention of Lyme disease. TP-05 is currently being studied in a Phase 2a clinical trial and TP-04 is scheduled to begin a Phase 2 clinical trial in 2025 to evaluate safety, tolerability and proof of activity.

If you are looking for an opportunity to work alongside a diverse team with deep expertise, have a curious and driven mindset and a passion for helping patients, then join our Tarsus community and help build our unique culture!